# Safety/Tolerability and Pharmacokinetics/Pharmacodynamics of YH4808 After Oral Administration in Healthy Male Subjects

> **NCT01007019** · PHASE1 · COMPLETED · sponsor: **Yuhan Corporation** · enrollment: 134 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** YH4808 30mg
- **DRUG:** YH4808 50mg
- **DRUG:** YH4808 100mg
- **DRUG:** YH4808 200mg
- **DRUG:** YH4808
- **DRUG:** YH4808 100mg (repeat dose)
- **DRUG:** YH4808 200mg (repeat dose)
- **DRUG:** YH4808 600mg
- **DRUG:** YH4808 800mg (single dose)
- **DRUG:** YH4808 400 mg (repeat doses)
- **DRUG:** Placebo
- **DRUG:** Esomeprazole 40mg

## Key facts

- **NCT ID:** NCT01007019
- **Lead sponsor:** Yuhan Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-11
- **Primary completion:** 2011-03
- **Final completion:** 2012-03
- **Target enrollment:** 134 (ACTUAL)
- **Last updated:** 2014-07-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01007019

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01007019, "Safety/Tolerability and Pharmacokinetics/Pharmacodynamics of YH4808 After Oral Administration in Healthy Male Subjects". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01007019. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*